Evaxion Wins Enabling Technology Leadership Award

[Helge_LarsenPI-redaktør]

Pressemeddelelse d. 14. oktober 2021

Evaxion Biotech A/S (NASDAQ: EVAX) a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today it has been awarded this year's Enabling Technology Leadership Award in the artificial intelligence-enabled drug discovery industry by global research and consulting firm Frost & Sullivan. The award recognizes Evaxion's pioneering spirit towards cutting-edge technology and data-driven decision-making.
Lars Wegner, CEO of Evaxion, said: "We are honored to receive this prestigious award from Frost & Sullivan and I am very proud of the hard work and commitment of the whole Evaxion team in advancing our vision for better global health. We believe that through our deep understanding of the immune system and our AI-capabilities, we can redefine the discovery and development of immunotherapies and impact the lives of patients."

Frost & Sullivan analysts highlighted how Evaxion's proprietary AI-immunology platforms, PIONEERTM, EDENTM, and RAVENTM, translate data helping to create a deeper understanding of the human immune system to rapidly design novel immunotherapies more efficiently.
Darrell Huntsman, CEO of Frost & Sullivan, said: "We identify companies that consistently develop growth strategies based on a visionary understanding of the future, and thus more effectively address new challenges and opportunities. Evaxion sets an impressive benchmark to follow in the AI-enabled drug discovery space and will continue to push boundaries in the years to come, and we are pleased to recognize the company for its valuable achievements."

About Evaxion
Evaxion Biotech A/S is a clinical-stage AI-immunologyTM platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer, bacterial diseases and viral infections. Based on its proprietary and scalable AI-immunology core technology, Evaxion is developing a broad pipeline of novel product candidates which currently includes three patient-specific cancer immunotherapies, two of which are in Phase 1/2a clinical development. In addition, Evaxion is advancing a portfolio of vaccines to prevent bacterial and viral infections currently in preclinical development.

Kontaktinformation
Morten Huse Eikrem-Jeppesen, PressConnect, mobil 53 85 07 70

[Makingmoney]

Evaxion jeg synes stadig den er vildt interessant https://www.proinvestor.com/boards/91684/For-Biotek-tosser

[HanneP]

Jeg er med på grund af bredden i pipelinen. Får man ikke succes med det ene er der noget andet at falde tilbage på.

[Stroka]

Netop Hanne, Det er ikke en "one-trick-pony". Dem er der mange af indenfor biotek.

[deleted-user]

Jeg fik denne anbefalet af en som har ret godt styr på forskningen bag - måske knap så meget omkring langsigtede investeringer. Når jeg spørger ind til likviditet og hvornår denne udløber, så har min anbefaling ikke så mange svar. Jeg er pænt ringe til at gennemskue det i biotek (man skal kende sine begrænsninger). Hvad siger debatten her?
Det jeg har indtil videre er ikke godt nok til at "gå ind", men "lokkes" jeg 2-3 år ud i tiden med den viden jeg har, så kan jeg godt se fremtiden for mig

[Makingmoney]

Niels C De skal helt sikkert ud at hente penge, flere gange. Sådan er biotek. Det er svært at sige noget om deres cashburn,likviditet idet de er nye på børsen. Før børsnoteringen havde de ingen kvaler med at skaffe penge, ej heller i.f.m noteringen. Cashburn afhænger jo af igangværende forsøg, det antal kan ses på hjemmesiden, nye kan sikkert forudsiges/forventes ved at følge kvartals rapporter. Jeg tror de bliver opkøbt/fusionere indenfor et til to år.
Spring da på, om ikke andet med et frimærke